Browse HSD17B8

Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion matrix
Domain -
Function

NAD-dependent 17-beta-hydroxysteroid dehydrogenase with highest activity towards estradiol. Has very low activity towards testosterone (PubMed:17978863). The heterotetramer with CBR4 has NADH-dependent 3-ketoacyl-acyl carrier protein reductase activity, and thereby plays a role in mitochondrial fatty acid biosynthesis (PubMed:19571038, PubMed:25203508). Within the heterotetramer, HSD17B8 binds NADH; CBR4 binds NADPD (PubMed:25203508).

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006694 steroid biosynthetic process
GO:0006703 estrogen biosynthetic process
GO:0008202 steroid metabolic process
GO:0008209 androgen metabolic process
GO:0008210 estrogen metabolic process
GO:0010817 regulation of hormone levels
GO:0016053 organic acid biosynthetic process
GO:0034754 cellular hormone metabolic process
GO:0042445 hormone metabolic process
GO:0042446 hormone biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0051259 protein oligomerization
GO:0051262 protein tetramerization
GO:0051290 protein heterotetramerization
GO:0051291 protein heterooligomerization
GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity
GO:0004303 estradiol 17-beta-dehydrogenase activity
GO:0016229 steroid dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0047025 3-oxoacyl-[acyl-carrier-protein] reductase (NADH) activity
GO:0047035 testosterone dehydrogenase (NAD+) activity
GO:0048037 cofactor binding
GO:0050662 coenzyme binding
GO:0051287 NAD binding
GO:0070404 NADH binding
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00140 Steroid hormone biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HSD17B8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HSD17B8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HSD17B8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.8620.0189
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6220.501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.0350.164
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2870.49
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3570.779
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.190.891
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1750.569
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.10.912
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5630.603
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5870.71
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.9470.677
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0120.908
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HSD17B8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HSD17B8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HSD17B8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HSD17B8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HSD17B8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HSD17B8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HSD17B8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHSD17B8
Namehydroxysteroid (17-beta) dehydrogenase 8
Aliases HKE6; D6S2245E; KE6; H2-KE6; SDR30C1; short chain dehydrogenase/reductase family 30C, member 1; FABGL; FabG ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HSD17B8 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HSD17B8.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB034612'-Monophosphoadenosine 5'-DiphosphoriboseSmall MoleculeADH1B, AKR1A1, AKR1B1, AKR1B10, AKR1C1, AKR1C2, AKR1C3, BLVRB, CRY ......28